Business Context and Reporting Period
Company: The Coca-Cola Company (KO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: A global total beverage company operating in more than 200 countries. The Company operates through two primary lines of business: concentrate operations (selling beverage bases to bottlers) and finished product operations (selling finished beverages to retailers). Operating segments include Europe, Middle East & Africa; Latin America; North America; Asia Pacific; Global Ventures; and Bottling Investments. In November 2024, the Company announced plans to sunset the Global Ventures operating segment, integrating its results into other geographic segments effective January 1, 2025.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Operating Revenues | $47,061 million | $45,754 million | +3% |
| Gross Profit | $28,737 million | $27,234 million | +6% |
| Gross Profit Margin | 61.1% | 59.5% | +160 bps |
| Operating Income | $9,992 million | $11,311 million | -12% |
| Operating Margin | 21.2% | 24.7% | -350 bps |
| Net Income (Attributable to Shareowners) | $10,631 million | $10,714 million | -1% |
| Diluted EPS | $2.46 | $2.47 | -0.4% |
| Operating Cash Flow | $6,805 million | $11,599 million | -41% |
| Capital Expenditures | $2,064 million | $1,852 million | +11% |
| Total Debt (Long-term + Current) | $43,023 million | $37,507 million | +15% |
| Cash & Equivalents | $10,828 million | $9,366 million | +16% |
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 3% driven by a favorable 11% impact from price, product, and geographic mix, partially offset by a 5% unfavorable impact from foreign currency exchange rates and a 4% impact from acquisitions and divestitures.
- Volume Performance: Worldwide unit case volume increased 1% to 33.7 billion cases. Concentrate sales volume also grew 1%. Growth was led by Latin America (+3%) and Asia Pacific (+1%), while North America and Europe, Middle East & Africa remained flat.
- Operating Income Decline: Operating income decreased 12% primarily due to higher commodity costs, increased selling, general, and administrative (SG&A) expenses, and significantly higher "Other Operating Charges."
- Other Operating Charges: Charges increased to $4,163 million in 2024 from $1,951 million in 2023. Key drivers included:
- $3,109 million related to the remeasurement of contingent consideration for the fairlife acquisition.
- $760 million impairment charge for the BodyArmor trademark.
- $133 million for productivity and reinvestment programs.
- $126 million impairment of a trademark in Latin America.
- Cash Flow Impact: Operating cash flow decreased 41% largely due to a $6.0 billion deposit paid to the IRS regarding a tax litigation dispute (2007-2009 tax years), which is recorded as a non-current asset and expected to be refunded if the Company prevails on appeal.
Guidance, Outlook, and Risks
- Dividend: The Board increased the quarterly dividend to $0.51 per share (annualized $2.04), marking the 63rd consecutive annual increase.
- Capital Allocation: Priorities include investing in business operations, growing dividends, consumer-centric acquisitions, and share repurchases to offset dilution. 2025 capital expenditures are expected to be approximately $2.2 billion.
- Tax Litigation Risk: The Company is in litigation with the IRS regarding transfer pricing for tax years 2007-2009. The Tax Court ruled against the Company, resulting in a $6.0 billion liability (including interest). The Company paid this amount in September 2024 and has appealed. Management believes it is "more likely than not" to prevail, but notes that if the Tax Court methodology is applied to subsequent years (2010-2024), the potential aggregate remaining incremental tax and interest liability could be approximately $12 billion.
- Foreign Exchange: A stronger U.S. dollar negatively impacted revenues and operating income in 2024. Management expects foreign currency fluctuations to have an unfavorable impact on full-year 2025 net operating revenues.
- Operational Changes: The Company continues to refranchise bottling operations (e.g., Philippines, Bangladesh, India) to streamline the system, which impacts the Bottling Investments segment volume and revenue recognition.
Key Facts for Investor Verification
- IRS Tax Dispute Status: Verify the progress of the appeal to the U.S. Court of Appeals for the Eleventh Circuit regarding the $6.0 billion tax deposit and the potential $12 billion exposure for subsequent years.
- BodyArmor Impairment: Monitor future operating results of the BodyArmor trademark, as the $760 million impairment was driven by revised projections and higher discount rates; further impairments are possible if projections are not met.
- fairlife Contingent Consideration: Track the fairlife acquisition milestone payment liability, which fluctuates based on operating results and significantly impacted 2024 operating income.
- Refranchising Impact: Assess the long-term impact of refranchising bottling operations on the Company's revenue mix (shifting from finished product to concentrate sales) and operating margins.
- Commodity Costs: Monitor inflationary pressures on sweeteners, packaging, and energy, which contributed to the decline in operating margin despite favorable pricing initiatives.